Phase 1 study of TraceNETTM in neuroendocrine tumours patients
Latest Information Update: 29 Mar 2023
At a glance
- Drugs 61Cu based TraceNET radiodiagnostic (Primary) ; Gallium 68-DOTATOC
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Diagnostic use; First in man; Pharmacokinetics
Most Recent Events
- 29 Mar 2023 New trial record
- 21 Mar 2023 According to a Trophic Communications media release, Prof. Melpomeni Fani is the principal investigator for this trial.
- 21 Mar 2023 According to a Trophic Communications media release, Neuroendocrine Tumors Research Foundation ("NETRF") has selected the NUCLIDIUM and its collaboration partner the University Hospital Basel as recipients of its Investigator Award which will support the initiation and execution of this trial